Bhidayasiri R, Phokaewvarangkul O, Lim T, Pal P, Watanabe H, Cho J
J Mov Disord. 2024; 17(3):262-269.
PMID: 38600683
PMC: 11300398.
DOI: 10.14802/jmd.24068.
Barer Y, Ribalov R, Yaari A, Maor R, Arow Q, Logan J
J Clin Psychopharmacol. 2022; 42(5):454-460.
PMID: 36018237
PMC: 9426751.
DOI: 10.1097/JCP.0000000000001597.
Vaiman E, Shnayder N, Novitsky M, Dobrodeeva V, Goncharova P, Bochanova E
Biomedicines. 2021; 9(8).
PMID: 34440083
PMC: 8389582.
DOI: 10.3390/biomedicines9080879.
Caligiuri M, Teulings H, Dean C, Lohr J
Psychiatry Res. 2019; 273:537-543.
PMID: 30710809
PMC: 6561794.
DOI: 10.1016/j.psychres.2019.01.058.
Ward K, Citrome L
Neurol Ther. 2018; 7(2):233-248.
PMID: 30027457
PMC: 6283785.
DOI: 10.1007/s40120-018-0105-0.
The Assessment and Treatment of Antipsychotic-Induced Akathisia.
Pringsheim T, Gardner D, Addington D, Martino D, Morgante F, Ricciardi L
Can J Psychiatry. 2018; 63(11):719-729.
PMID: 29685069
PMC: 6299189.
DOI: 10.1177/0706743718760288.
Comments on Lucire and Crotty, 2011.
Loonen A, Verkes R
Pharmgenomics Pers Med. 2016; 9:85-7.
PMID: 27574461
PMC: 4993408.
DOI: 10.2147/PGPM.S111666.
A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study.
Weiden P, Manning R, Wolfgang C, Ryan J, Mancione L, Han G
CNS Drugs. 2016; 30(8):735-47.
PMID: 27379654
PMC: 4982888.
DOI: 10.1007/s40263-016-0345-4.
Evaluation of an Educational Program for Clinical Pharmacists to Conduct Standardized Assessments for Medication-Induced Movement-Related Disorders.
Spadaro A, Kellar J, Remington G, Sproule B, Al-Sukhni M, Chaiet A
Can J Hosp Pharm. 2015; 68(3):258-64.
PMID: 26157190
PMC: 4485516.
DOI: 10.4212/cjhp.v68i3.1461.
Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development.
Bush S, Kanji S, Pereira J, Davis D, Currow D, Meagher D
J Pain Symptom Manage. 2014; 48(2):231-248.
PMID: 24480529
PMC: 4081457.
DOI: 10.1016/j.jpainsymman.2013.07.018.
Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies.
Kane J, Kishimoto T, Correll C
World Psychiatry. 2013; 12(3):216-26.
PMID: 24096780
PMC: 3799245.
DOI: 10.1002/wps.20060.
Drug-induced parkinsonism in the elderly: incidence, management and prevention.
Lopez-Sendon J, Mena M, Garcia de Yebenes J
Drugs Aging. 2012; 29(2):105-18.
PMID: 22250585
DOI: 10.2165/11598540-000000000-00000.
Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.
Woods S, Morgenstern H, Saksa J, Walsh B, Sullivan M, Money R
J Clin Psychiatry. 2010; 71(4):463-74.
PMID: 20156410
PMC: 3109728.
DOI: 10.4088/JCP.07m03890yel.
Lesson of the week: Akathisia: overlooked at a cost.
Akagi H, Kumar T
BMJ. 2002; 324(7352):1506-7.
PMID: 12077042
PMC: 1123446.
DOI: 10.1136/bmj.324.7352.1506.
Drug-induced movement disorders.
Jimenez-Jimenez F, Garcia-Ruiz P, Molina J
Drug Saf. 1997; 16(3):180-204.
PMID: 9098656
DOI: 10.2165/00002018-199716030-00004.
Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose.
Egan M, Hyde T, Kleinman J, Wyatt R
Psychopharmacology (Berl). 1995; 117(1):74-81.
PMID: 7724705
DOI: 10.1007/BF02245101.
A case of neuroleptic-induced laryngospasm.
Garcia M, Mercer P
West J Med. 1990; 153(4):438-9.
PMID: 1978764
PMC: 1002584.
Neuroleptic medication and prescription practices with sheltered-care residents: a 12-year perspective.
Segal S, Cohen D, Marder S
Am J Public Health. 1992; 82(6):846-52.
PMID: 1350181
PMC: 1694183.
DOI: 10.2105/ajph.82.6.846.